Zim Laboratories Limited has informed the Exchange about Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 20.3 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zim Laboratories Limited has received Marketing Authorization from Australia's Therapeutic Goods Administration (TGA) for its Tamsulosin Hydrochloride and Dutasteride Capsules, a urology product used to treat enlarged prostate (BPH) in men. The approval was secured through its Australian subsidiary ZIMTAS PTY LTD and marks the company's second Marketing Authorization in Australia. The fixed-dose combination combines two active ingredients into a single daily dose, aimed at improving patient compliance. The company expects this to enable a commercial launch in Australia and support further regulatory submissions in other APAC and international markets. The move aligns with Zim Labs' strategy to expand its presence in regulated markets using its proprietary drug delivery technologies.
Positive development for shareholders — opens a new revenue stream in the Australian market, strengthens the company's urology portfolio, and supports its international expansion strategy. Could improve earnings visibility if commercial launch is executed well.